Action Rakovina Therapeutics - RKV

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,13

Prix Achat

0,125

Prix Vente

0,145

Volume échangé

288 000

0,11 Fourchette du Jour 0,145

0,00 Plage de 52 semaines 0,00

Cap du marché

9,111M

Clôture Veille

0,125

Ouverture

0,12

Dernière Transaction

1000

0.13

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

70 084 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-5,36

Bénéfice par action (BPA)

-0,04

Chiffre d'affairess

Bénéfice net

-2,61M

Secteur

Unit Inv Tr, Closed-end Mgmt

Industrie

Unit Inv Tr, Closed-end Mgmt

Site Web

www.rakovinatherapeutics.com

Siège social

Vancouver, British Columbia, Can

Fondé

Rakovina Therapeutics Inc est coté dans le secteur Unit Inv Tr, Closed-end Mgmt de la TSX Venture Exchange avec le ticker RKV. Le dernier cours de clôture d'Rakovina Therapeutics était de $0,13. Au cours de la dernière année, les actions de Rakovina Therapeutics ont été négociées dans une fourchette de prix de $ 0,00 à $ 0,00.

Rakovina Therapeutics compte actuellement 70 084 000 actions en circulation. La capitalisation boursière d'Rakovina Therapeutics est de $8,76 million. Rakovina Therapeutics a un ratio cours/bénéfice (ratio PE) de -5.36.

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture...

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company...

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new...

Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to...

Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies...

Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to...

Rakovina Therapeutics Announces Private Placement Offering

VANCOUVER, British Columbia, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to...

Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new...

Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas

VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new...

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CPLCopper Lake Resources Ltd	$ 0,01 (100,00%)	3k
AUGCAU Gold Corp	$ 0,01 (100,00%)	329k
MTKMontauk Metals Inc	$ 0,01 (100,00%)	145k
KEN.HKenadyr Metals Corp	$ 0,02 (100,00%)	100k
FUNDKatipult Technology Corp	$ 0,01 (100,00%)	23,23k
STMPStamper Oil and Gas Corp	$ 0,015 (-50,00%)	336k
ADG.HArcus Development Group Inc	$ 0,005 (-50,00%)	23,5k
TVC.HThree Valley Copper Corp	$ 0,005 (-50,00%)	21,9k
DMDataMetrex AI Limited	$ 0,005 (-50,00%)	223,42k
FTIFTI Foodtech International Inc	$ 0,115 (-42,50%)	6k
MATEBlockmate Ventures Inc	$ 0,285 (96,55%)	10,11M
LOULucero Energy Corp	$ 0,425 (1,19%)	8,51M
QNCQuantum Emotion Corp	$ 0,68 (-6,85%)	4,57M
FMCForum Energy Metals Corp	$ 0,055 (-15,38%)	4,56M
RUGRugby Resources Ltd	$ 0,02 (-20,00%)	3,04M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Rakovina Therapeutics Inc (RKV)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Rakovina Therapeutics Inc

RKV Dernières nouvelles

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

Rakovina Therapeutics Announces Private Placement Offering

Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain

Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update

Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

Rakovina Therapeutics Announces Private Placement Offering

Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Rakovina Therapeutics Inc (RKV) Cours

Rakovina Therapeutics Inc (RKV)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Rakovina Therapeutics Inc

RKV Dernières nouvelles

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS